Logan Capital Management Inc. Has $1.09 Million Stake in Lantheus Holdings, Inc. $LNTH

Logan Capital Management Inc. decreased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 49.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,330 shares of the medical equipment provider’s stock after selling 12,989 shares during the period. Logan Capital Management Inc.’s holdings in Lantheus were worth $1,091,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Signaturefd LLC increased its stake in shares of Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 116 shares during the period. Quarry LP increased its stake in shares of Lantheus by 2,350.0% in the first quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 470 shares during the period. Hughes Financial Services LLC acquired a new stake in shares of Lantheus in the first quarter valued at about $81,000. GAMMA Investing LLC increased its stake in shares of Lantheus by 29.3% in the first quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock valued at $128,000 after buying an additional 298 shares during the period. Finally, AlphaQuest LLC increased its stake in shares of Lantheus by 252.5% in the first quarter. AlphaQuest LLC now owns 1,653 shares of the medical equipment provider’s stock valued at $161,000 after buying an additional 1,184 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Transactions at Lantheus

In other news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. This trade represents a 49.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,812,000 shares of company stock worth $382,427,380 in the last three months. Insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on LNTH. Truist Financial set a $63.00 price target on Lantheus and gave the stock a “hold” rating in a report on Monday, August 11th. B. Riley decreased their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, September 16th. William Blair reiterated a “market perform” rating on shares of Lantheus in a report on Wednesday, July 16th. TD Cowen decreased their price target on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, September 15th. Finally, The Goldman Sachs Group set a $77.00 price target on Lantheus and gave the stock a “neutral” rating in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $74.50.

Lantheus Price Performance

LNTH stock opened at $57.33 on Wednesday. The stock has a market capitalization of $3.90 billion, a PE ratio of 15.25 and a beta of 0.09. The company’s 50-day moving average is $54.23 and its 200-day moving average is $71.05. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $92.51 million for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. Equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.